Latest news

  Up to $100 million of non-dilutive capital from Oxford Finance LLC Extends expected cash runway to mid-2024 SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX),

Five posters include data across biomarker, target engagement, and mechanism studies supporting development of PLN-74809, a dual-selective inhibitor of αvβ6/αvβ1 integrins, in IPF Pliant selected

  During Thursday, 849 stocks hit new 52-week lows.

  On Tuesday, 242 companies hit new 52-week lows.

    On Thursday, 92 companies hit new 52-week lows.

  During Tuesday's session, 454 stocks hit new 52-week lows.

    During Tuesday's trading, 505 companies set new 52-week lows.

    On Friday, 313 companies hit new 52-week lows.

Enrollment complete in INTERGRIS-IPF Phase 2a clinical trial with top-line data expected mid-2022 FDA has authorized evaluation of long-term treatment with PLN-74809 at doses up to 320 mg in IPF Company will present